{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:48:28Z","timestamp":1762206508787,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jid.2020.01.033","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T05:07:53Z","timestamp":1595308073000},"page":"1498-1500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Vitiligo: Targeted Therapies Add\u00a0Color to Disease Pathophysiology"],"prefix":"10.1016","volume":"140","author":[{"given":"Khaled","family":"Ezzedine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence M.","family":"Vance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrar A.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.01.033_bib1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.18.01223","article-title":"Markedly reduced risk of internal malignancies in patients with vitiligo: a nationwide population-based cohort study","volume":"37","author":"Bae","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.01.033_bib2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2020.01.033_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2020.01.033_bib4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaci.2017.07.011","article-title":"Vitiligo: mechanistic insights lead to novel treatments","volume":"140","author":"Frisoli","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2020.01.033_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","article-title":"Topical Janus kinase inhibitors: a review of applications in dermatology","volume":"79","author":"Hosking","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.01.033_bib6","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.01.033_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.01.033_bib7","doi-asserted-by":"crossref","first-page":"8978","DOI":"10.1200\/JCO.2005.01.6816","article-title":"Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients","volume":"23","author":"Luiten","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.01.033_bib8","article-title":"Apremilast is effective in controlling the progression of adult vitiligo: a case series","volume":"32","author":"Majid","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2020.01.033_bib9","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","author":"Mobasher","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.01.033_bib10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti-PD1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.01.033_bib11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.01.033_bib12","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2020.01.033_bib13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.01.033_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in\u00a0vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jid.2020.01.033_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.12111","article-title":"Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners","volume":"168","author":"Teulings","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.01.033_bib16","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.jid.2018.03.1511","article-title":"Inverse relationship between vitiligo-related genes and skin cancer risk","volume":"138","author":"Wu","year":"2018","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20302402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20302402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:43:44Z","timestamp":1762206224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20302402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0022202X20302402"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.01.033","relation":{},"ISSN":["0022-202X"],"issn-type":[{"type":"print","value":"0022-202X"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitiligo: Targeted Therapies Add\u00a0Color to Disease Pathophysiology","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2019.11.031","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}